Sign In
Buy DRMA
$1.27
-0.0900 (-6.62%)
At Close: Jun 03, 2026
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
08:00am, Wednesday, 22'nd Jan 2025
SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment o
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
09:00am, Monday, 16'th Dec 2024
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ACCESSWIR
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
09:00am, Tuesday, 10'th Dec 2024
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne - - Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 stud
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
04:15pm, Wednesday, 13'th Nov 2024
- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial - - Dermata continues discussions with potential botulinum toxin partners fo
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024
08:35am, Monday, 11'th Nov 2024
– Dermata Therapeutics invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com – – Dermata Therapeutics invites indiv
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
04:15pm, Tuesday, 08'th Oct 2024
SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medi
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
05:15pm, Tuesday, 17'th Sep 2024
Dermata raises approximately $7.8 million in gross proceeds since May 2024 - expected to fund its operations into the second quarter of 2025 SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / Dermata T
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
09:00pm, Monday, 16'th Sep 2024
SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of m
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
04:05pm, Thursday, 05'th Sep 2024
SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical a
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
04:05pm, Wednesday, 07'th Aug 2024
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - Dermata continues discussions with potential botulinum toxin partners for DMT410 - Rai
Why Is Dermata Therapeutics (DRMA) Stock Up 200% Today?
07:55am, Wednesday, 24'th Jul 2024
Dermata Therapeutics (NASDAQ: DRMA ) stock is taking off on Wednesday alongside heavy pre-market trading of the late-stage medical dermatology company's shares. This has more than 13 million shares o
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
09:00am, Wednesday, 17'th Jul 2024
- STAR-1 topline results expected in first quarter of 2025 - - About 30 million acne patients seek treatment in the U.S. each year - - DMT310, if approved, could be the first once-weekly topical produ
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
08:30am, Friday, 17'th May 2024
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
04:05pm, Wednesday, 15'th May 2024
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Recei
Dermata to Present at the Emerging Growth Conference on April 3, 2024
04:05pm, Wednesday, 27'th Mar 2024
- Dermata to provide a corporate update followed by a live question and answer session - SAN DIEGO, CA / ACCESSWIRE / March 27, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the
